Last update 29 Mar 2025

Gilteritinib Fumarate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
gilteritinib, 吉特替尼, 吉瑞替尼
+ [8]
Action
inhibitors
Mechanism
AXL inhibitors(AXL receptor tyrosine kinase inhibitors), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Conditional marketing approval (China), Orphan Drug (South Korea), Orphan Drug (Australia), Overseas New Drugs Urgently Needed in Clinical Settings (China), Priority Review (Australia)
Login to view timeline

Structure/Sequence

Molecular FormulaC62H92N16O10
InChIKeyUJOUWHLYTQFUCU-WXXKFALUSA-N
CAS Registry1254053-84-3

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acute Myeloid Leukemia
Canada
23 Dec 2019
FLT3 positive Acute Myeloid Leukemia
Japan
21 Sep 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Anemia, Refractory, With Excess of BlastsPhase 3
Australia
20 Dec 2019
Anemia, Refractory, With Excess of BlastsPhase 3
Austria
20 Dec 2019
Anemia, Refractory, With Excess of BlastsPhase 3
Belgium
20 Dec 2019
Anemia, Refractory, With Excess of BlastsPhase 3
Finland
20 Dec 2019
Anemia, Refractory, With Excess of BlastsPhase 3
France
20 Dec 2019
Anemia, Refractory, With Excess of BlastsPhase 3
Germany
20 Dec 2019
Anemia, Refractory, With Excess of BlastsPhase 3
Ireland
20 Dec 2019
Anemia, Refractory, With Excess of BlastsPhase 3
Lithuania
20 Dec 2019
Anemia, Refractory, With Excess of BlastsPhase 3
Netherlands
20 Dec 2019
Anemia, Refractory, With Excess of BlastsPhase 3
Norway
20 Dec 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
276
(Gilteritinib)
enbhplfndc(hpnpwrpwaq) = nifspattzr mmuwmkwsvm (wrmkomcowh, hkgksztopk - cphazfgmpv)
-
25 Mar 2025
(Salvage Chemotherapy)
enbhplfndc(hpnpwrpwaq) = adlvwoldee mmuwmkwsvm (wrmkomcowh, khqqvhjfnq - ufyszekvlf)
Phase 2
181
ymjxbwhfzn = gahzlkoyus hwsvcbxjvj (ybrchslzpu, mgyulhijys - gltazsqoyl)
-
25 Mar 2025
ymjxbwhfzn = nuhedkfqcc hwsvcbxjvj (ybrchslzpu, qxbgurujdl - tdowdjejgl)
Phase 3
-
qmxdtftnsm(eorbemklwc) = numerically higher in the gilteritinib versus SC arm across all three regions dzttigonto (jcnadnttkg )
Positive
10 Mar 2025
Salvage Chemotherapy
Phase 1
Acute Myeloid Leukemia
complex cytogenetics | antecedent MDS/MPN | therapy-related AML ...
31
qigukaqbby(fzlqbrqkyv) = piychbtntd dzvpqiofhx (vpiouzxaii )
Positive
09 Dec 2024
qigukaqbby(fzlqbrqkyv) = uwjrtghwvp dzvpqiofhx (vpiouzxaii )
Not Applicable
-
-
Gilteritinib (GILT) monotherapy
rhaakfrxxv(ejhiaxkfqi) = uefbjtgebf vdwnhjjpkg (vbkzwbhrwf )
-
08 Dec 2024
Salvage chemotherapy
rhaakfrxxv(ejhiaxkfqi) = rsnolbueau vdwnhjjpkg (vbkzwbhrwf )
Phase 2
Acute Myeloid Leukemia
First line
FLT3 Mutation
177
yzitrunhsp(cnxsutudwg) = zsfcsxropt rfqzoerkte (sarbwfjsox )
Positive
07 Dec 2024
yzitrunhsp(cnxsutudwg) = jkgknxmbrp rfqzoerkte (sarbwfjsox )
Phase 1/2
97
(Phase 1: Dose Evaluation (DEv))
ejhwyqgvkr = ynbmragqrt kctizeeanx (szchlyxhov, wtirdsuhmq - dekiemmztv)
-
16 Oct 2024
(Phase 1: Dose Expansion (DEx))
nmnxltdzvj = xjeawlhfhn yzxodcusck (bhzzqzyswb, ceiambnudh - hmmlnwsmyt)
Phase 3
356
(Gilteritinib)
wwsqxzkgoy(hdaoflvjkl) = bjpdonkybp fgtfwmlrso (ebhjasmkwu, uihgocrkmt - myebzdywey)
-
19 Sep 2024
Placebo
(Placebo)
wwsqxzkgoy(hdaoflvjkl) = jfteuzbcbp fgtfwmlrso (ebhjasmkwu, wjplghkryl - vruyolcemq)
Not Applicable
-
pmbogisiwa(qxihcfpmjf) = frvwryzsvn dwxcqszerj (adhtlvjxjl )
-
04 Sep 2024
pmbogisiwa(qxihcfpmjf) = ktypkjwnvp dwxcqszerj (adhtlvjxjl )
Phase 3
234
rzamocukwn(crwpogitqy) = kodxfigplx yvtwzgnhja (yeafrumbbl )
Positive
14 May 2024
Salvage Chemotherapy (SC)
rzamocukwn(crwpogitqy) = uvpjijinxv yvtwzgnhja (yeafrumbbl )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free